Zinc improves Denosumab and eldecalcitol efficacy for bone mineral density in patients with hypozincemia

Ishizu, Hotaka; Shimizu, Tomohiro; Ohashi, Yusuke; Kusunoki, Kenichi; Kanayama, Masahiro; Iwasaki, Norimasa; Oha, Fumihiro

Zinc improves Denosumab and eldecalcitol efficacy for bone mineral density in patients with hypozincemia

Ishizu, Hotaka; Shimizu, Tomohiro; Ohashi, Yusuke et al.

Journal of bone and mineral metabolism, 2024, 42(2), 233-241

Permalink : https://hdl.handle.net/2115/94709

このアイテムのアクセス数:144件（2026-07-12 14:28 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
HUSCAP_JBMM 2024 Ishizu	pdf	591 KB	141
SupTable 1	docx	20.1 KB	34

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/94709
タイトル	Zinc improves Denosumab and eldecalcitol efficacy for bone mineral density in patients with hypozincemia
著者	Ishizu, Hotaka ; Shimizu, Tomohiro ; Ohashi, Yusuke ; Kusunoki, Kenichi ; Kanayama, Masahiro ; Iwasaki, Norimasa ; Oha, Fumihiro
著者名 Ishizu, Hotaka
e-Rad_Researcher 60784246 著者名 Shimizu, Tomohiro
著者名 Ohashi, Yusuke
著者名 Kusunoki, Kenichi
著者名 Kanayama, Masahiro
e-Rad_Researcher 30322803 著者名 Iwasaki, Norimasa
著者名 Oha, Fumihiro
言語	英語
キーワード	Bone mineral density
	Denosumab
	Hypozincemia
	Osteoporosis
	Zinc
発行日	2024-03-01
出版者	Springer
収録物名	Journal of bone and mineral metabolism
巻(号)	42(2)
ページ	233-241
抄録	Introduction We aimed to investigate the effects of zinc deficiency and zinc medication in osteoporosis patients undergoing denosumab (DMAb). Materials and methods This retrospective study was conducted at a single hospital. The participants were female osteoporosis patients visiting between April 2019 and April 2020. All patients were treated with DMAb and eldecalcitol and recommended zinc-rich food. Based on zinc medication and serum zinc levels at the 12th month of dietary guidance, patients were categorized into the following four groups: hypozincemia with zinc medication, latent zinc deficiency with zinc medication, without zinc medication, and control without zinc medication. Longitudinal serum zinc concentrations, bone mineral density (BMD), and occurrence of fractures were measured. We investigated the factors influencing no response to DMAb and eldecalcitol treatment. Results Among the 145 patients followed up for 24 months, dietary guidance did not change the serum zinc concentration; however, zinc medication significantly increased these levels. The hypozincemia group did not show a significant BMD increase in the lumbar spine and femoral neck after DMAb and eldecalcitol treatment during dietary guidance; however, zinc medication increased these to the same levels as the other groups. In multivariate analyses, hypozincemia and thyroid disease were identified as the factors affecting no response. While 28.2% of patients with latent zinc deficiency without zinc medication suffered fractures, no fractures occurred in hypozincemia patients with zinc medication. Conclusion Hypozincemia may reduce the efficacy of DMAb and eldecalcitol in increasing BMD and fracture prevention.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00774-024-01498-3
PISSN	0914-8779
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s00774-024-01498-3